ClinicalTrials.gg
CompletedNCT03740529Updated Jan 27, 2026

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

A Phase 1/2 interventional study of Pirtobrutinib and Venetoclax in Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia and Mantle Cell Lymphoma, sponsored by Loxo Oncology, Inc.. Completed at 56 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
803
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
Largest of 23
803 · median 87
Started
2019
the only one that year
Phase 1/2
2 of 23
none open now
Registered
1st of 23
by date
Lead sponsor
6 of 23
Loxo Oncology, Inc.

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 1st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Read the detailed description

This study includes 3 parts: Phase 1 (pirtobrutinib monotherapy dose escalation and dose expansion), Phase 1b (pirtobrutinib combination therapy dose expansion), and Phase 2 (pirtobrutinib monotherapy dose expansion). In Phase 1, patients will be enrolled using an accelerated titration design. The starting dose of pirtobrutinib in oral tablet form is 25 mg/day (e.g., 25 mg once daily [QD]). Once the MTD and/or RP2D is identified in Phase 1 dose escalation, enrollment will continue to Phase 1 dose expansion and can commence to Phase 1b (Arms A and B). For Phase 2, patients will be enrolled to one of seven Phase 2 dose expansion cohorts depending on tumor histology and prior treatment history. Cycle length will be 28 days.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Waldenstrom Macroglobulinemia
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • B-cell Lymphoma
  • Small Lymphocytic Lymphoma

Keywords

  • Loxo
  • LOXO-305
  • BTK
  • Bruton's tyrosine kinase
  • CLL
  • SLL
  • NHL
  • Chronic Lymphocytic Leukemia
  • C481S
  • C481
  • Ibrutinib
  • Acalabrutinib
  • Zanubrutinib
  • BGB-3111
  • GS-4059
  • ONO-4059
  • Tirabrutinib
  • Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Waldenstrom macroglobulinemia
  • Non-Hodgkin Lymphoma
  • BTK Intolerant
  • C481S Mutation
  • Marginal zone lymphoma
  • DLBCL (Diffuse Large B-cell lymphoma)
  • Follicular Lymphoma
  • PI3KD
  • Idelalisib
  • Umbralisib
  • BCL2
  • Venetoclax
  • Rituximab
  • Primary CNS Lymphoma
  • Richter's Transformation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).
  • Adequate hematologic function (Phase 1 and 1b Patients only).
  • Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).
  • Histologically confirmed /recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).
  • Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).
  • (ECOG) 0-2.
  • Adequate hepatic and renal function.
  • Ability to receive study drug therapy orally.
  • Willingness of men and women of (defined as following menarche and not [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective .

Exclusion criteria

Exclusion Criteria:

  • agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.
  • Major surgery within 4 weeks prior to planned start of specified study therapy.
  • Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.
  • Pregnancy or lactation.
  • Patients requiring therapeutic anticoagulation with warfarin.
  • Any unresolved toxicities from prior therapy greater than (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.
  • History of or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.
  • Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
  • Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.
  • , uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.
  • Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.
  • Patients who have tested positive for (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.
  • Clinically significant active malabsorption syndrome.
  • Current treatment with certain strong inhibitors or inducers and/or strong P-gp inhibitors.
  • For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.
  • Prior treatment with pirtobrutinib.
  • Active second unless in remission and with > 2 years.
  • Known to any component or of pirtobrutinib.
  • For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.
  • Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
803 participants (actual)

Study arms

  • Experimental
    Phase I Dose Escalation (Pirtobrutinib Monotherapy)

    Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 3

    CLL/SLL patients with no prior therapy.

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 1

    Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 4

    CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 2

    CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 5

    WM patients treated with a prior BTK inhibitor-containing regimen.

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 6

    MZL patients treated with a prior BTK inhibitor-containing regimen.

    Drug: Pirtobrutinib

  • Experimental
    Phase 2 (Pirtobrutinib Monotherapy) Cohort 7

    Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.

    Drug: Pirtobrutinib

  • Experimental
    Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A

    Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax

    Drug: Pirtobrutinib · Drug: Venetoclax

  • Experimental
    Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B

    Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab

    Drug: Pirtobrutinib · Drug: Venetoclax · Drug: Rituximab

  • Experimental
    Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)

    Patients to receive the recommended Phase 2 dose of pirtobrutinib

    Drug: Pirtobrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Phase I

    Time frame: Up to 24 Months

  2. Recommended dose for further study

    Phase I

    Time frame: Up to 24 Months

  3. To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).

    Phase II

    Time frame: Up to 24 months

  4. To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0

    For Phase 1b

    Time frame: Up to 24 Months

  5. To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0

    For Phase 1b

    Time frame: Up to 24 Months

Secondary outcomes

  1. To determine the safety profile and tolerability of pirtobrutinib including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events.

    Phase I

    Time frame: Up to 24 Months

  2. To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.

    Phase I

    Time frame: Up to 24 Months

  3. To assess the preliminary anti-tumor activity of pirtobrutinib based on overall response rate (ORR) as assessed by investigator.

    Phase I

    Time frame: Up to 24 Months

  4. ORR as assessed by the Investigator.

    Phase II

    Time frame: Up to 24 Months

  5. Best overall response (BOR) as assessed by the Investigator and IRC.

    Phase II

    Time frame: Up to 24 Months

  6. Duration of response (DOR) as assessed by the Investigator and IRC.

    Phase II

    Time frame: Up to 24 Months

  7. Progression free survival (PFS) as assessed by the Investigator and IRC.

    Phase II

    Time frame: Up to 24 Months

  8. Overall survival (OS).

    Phase II

    Time frame: Up to 24 Months

  9. To determine the safety profile and tolerability of pirtobrutinib including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events

    Phase II

    Time frame: Up to 24 Months

  10. To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.

    Phase II

    Time frame: Up to 24 Months

  11. To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.

    For Phase 1b

    Time frame: Up to 24 months

  12. To assess the preliminary anti-tumor activity of pirtobrutinib in combination based on overall response rate (ORR) as assessed by investigator.

    For Phase 1b

    Time frame: Up to 24 months

  13. Symptomatic Response: Change from Baseline in Mantle Cell Lymphoma (MCL)-related symptoms selected from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library

    Individual EORTC symptom scores range from 1 (not at all) to 4 (very much) with higher scores representing more severe symptom severity.

    Time frame: Baseline, End of Treatment (Estimated Up to 24 Months)

  14. Functional Response: Change from Baseline in Physical Functioning as Measured by Physical Functioning Scale from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ)

    EORTC physical function item scores range from 1 (not at all) to 4 (very much) with higher scores indicating poorer functioning.The total EORTC physical functioning score ranges from 0-100 where a higher score indicates higher/healthier level of functioning.

    Time frame: Baseline, End of Treatment (Estimated Up to 24 Months)

07

Study locations

56 sites
  • Mayo Clinic of Scottsdale
    Scottsdale, Arizona 85259, United States
  • Scripps Coastal Medical Center
    San Diego, California 92103, United States
  • University of California San Francisco, Medical Center at Paranassus
    San Francisco, California 94117, United States
  • Smilow Cancer Hospital at Yale-New Haven
    New Haven, Connecticut 06510, United States
  • Mayo Clinic-Jacksonville
    Jacksonville, Florida 32224, United States
  • Florida Cancer Specialists ORLANDO/DDU
    Lake Mary, Florida 32746, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Emory Clinic
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic
    Rochester, Minnesota 55905-0002, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68105, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Northwell Health
    New Hyde Park, New York 11042, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Durham VA Medical Center
    Durham, North Carolina 27705, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University Hospital
    Columbus, Ohio 43210, United States
  • University of Pennsylvania Hospital
    Philadelphia, Pennsylvania 19104, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98195, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
    Nantes, 44093, France
  • IRCCS - AOU di Bologna
    Bologna, 40138, Italy
  • IRCCS Ospedale San Raffaele
    Milan, 20132, Italy
  • Nagoya Medical Center
    Nagoya, Aichi-ken 460-0001, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Tokai University Hospital- Isehara Campus
    Isehara, Kanagawa 259-1193, Japan
  • Kochi Medical School Hospital
    Nankoku, Kochi 783-8505, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • National Cancer Center Hospital
    Chuo Ku, Tokyo 104-0045, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Kyoto Furitsu Medical University Hospital
    Kyoto, 602-8566, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
  • Kindai University Hospital
    Osakasayama-Shi, 589-8511, Japan
  • Pratia MCM Krakow
    Krakow, 30-510, Poland
  • Instytut Hermatologii I Transfuzjologii
    Warsaw, Poland
  • Samsung Medical Center
    Seoul, Seoul-teukbyeolsi [Seoul] 06351, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Karolinska Institutet
    Solna, AB 171 65, Sweden
  • Ospedale Regionale Bellinzona e Valli
    Bellinzona, Canton Ticino 6500, Switzerland
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LJ, United Kingdom
  • Derriford Hospital
    Plymouth, Pl6 8DH, United Kingdom
08

References and documents

Publications

  • Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, Scarfo L, Munir T, Lech-Maranda E, Hoffmann MS, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Rhodes JM, Vose J, McKinney M, Gerson JN, Barve MA, Kuss B, Koh Y, Barrett A, Treon SP, Castillo JJ, Seymour JF, Ruppert AS, McNeely SC, Walgren RA, Tsai DE, Bao K, Nair B, Woyach J, Cheah CY. Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstrom macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May;13(5):e284-e296. doi: 10.1016/S2352-3026(26)00037-2. PubMed 42069409 ↗
  • Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfo L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14;10(7):2441-2451. doi: 10.1182/bloodadvances.2025017489. PubMed 41544219 ↗
  • Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG. Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. Blood. 2026 Jan 1;147(1):24-34. doi: 10.1182/blood.2024027009. PubMed 41055698 ↗
  • Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025 Dec 9;9(23):5954-5964. doi: 10.1182/bloodadvances.2024014975. PubMed 40845254 ↗
  • Lamanna N, Tam CS, Woyach JA, Alencar AJ, Palomba ML, Zinzani PL, Flinn IW, Fakhri B, Cohen JB, Kontos A, Konig H, Ruppert AS, Chatterjee A, Sizelove R, Compte L, Tsai DE, Jurczak W. Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy. EJHaem. 2024 Sep 27;5(5):929-939. doi: 10.1002/jha2.1013. eCollection 2024 Oct. PubMed 39415923 ↗
  • Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep;11(9):e682-e692. doi: 10.1016/S2352-3026(24)00172-8. Epub 2024 Jul 18. PubMed 39033770 ↗
  • Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 Sep 26;144(13):1374-1386. doi: 10.1182/blood.2024024510. PubMed 38861666 ↗
  • Telaraja D, Kasamon YL, Collazo JS, Leong R, Wang K, Li P, Dahmane E, Yang Y, Earp J, Grimstein M, Rodriguez LR, Theoret MR, Gormley NJ. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma. Clin Cancer Res. 2024 Jan 5;30(1):17-22. doi: 10.1158/1078-0432.CCR-23-1272. PubMed 37624619 ↗
  • Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696. PubMed 37407001 ↗
  • Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-3997. doi: 10.1200/JCO.23.00562. Epub 2023 May 16. PubMed 37192437 ↗
  • Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 May 20;12(5):80. doi: 10.1038/s41408-022-00675-9. PubMed 35595730 ↗
  • Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. PubMed 34398557 ↗
  • Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. PubMed 33676628 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2025, 70 months.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's 70 months is below that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2018
First posted
Nov 14, 2018
StartActual
Mar 15, 2019
Primary completionActual
Jan 27, 2025
CompletionActual
Dec 23, 2025
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03740529
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Mar 15, 2019
Primary completion
Jan 27, 2025
Completion
Dec 23, 2025
Last update
Jan 27, 2026

Study contacts

Donald Tsai, MD, PhD
study director · Loxo Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion